Innoviva Inc reports results for the quarter ended in June - Earnings Summary

Innoviva

31/07/2024 22:15

* Innoviva Inc  INVA.OQ  reported a quarterly adjusted loss
of 55
cents​​ per share for the quarter ended in June, lower than the
same quarter last year, when the company reported EPS of 2
cents.  The mean expectation of two analysts for the quarter was
for earnings of 24 cents per share. Wall Street expected
results to range from 22 cents to 25 cents per share.
    * Revenue rose 23.3% to $99.90 million from a year ago;
analysts
expected $74.69 million. 
    * Innoviva Inc shares had risen by 15.8% this quarter and
gained 18.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 6.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is  "hold."

Wall Street's median 12-month price target for Innoviva Inc is
$16.00 
This summary was machine generated from LSEG data July 31 at
09:14 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      0.24           -0.55          Missed
 Mar. 31 2024      0.17           0.46           Beat
 Dec. 31 2023      0.23           0.76           Beat
 Sep. 30 2023      0.27           0.98           Beat